lucky fortune numbers
CAPE CANAVERAL, Fla. (AP) — Known across the globe as the stuck astronauts, Butch Wilmore and Suni Williams hit the six-month mark in space Thursday with two more to go. The pair rocketed into orbit on June 5, the first to ride Boeing’s new Starliner crew capsule on what was supposed to be a weeklong test flight. They arrived at the International Space Station the next day, only after overcoming a cascade of thruster failures and helium leaks . NASA deemed the capsule too risky for a return flight, so it will be February before their long and trying mission comes to a close. While NASA managers bristle at calling them stuck or stranded, the two retired Navy captains shrug off the description of their plight. They insist they’re fine and accepting of their fate. Wilmore views it as a detour of sorts: “We’re just on a different path.” “I like everything about being up here,” Williams told students Wednesday from an elementary school named for her in Needham, Massachusetts, her hometown. "Just living in space is super fun.” Both astronauts have lived up there before so they quickly became full-fledged members of the crew, helping with science experiments and chores like fixing a broken toilet, vacuuming the air vents and watering the plants. Williams took over as station commander in September. “Mindset does go a long way,” Wilmore said in response to a question from Nashville first-graders in October. He’s from Mount Juliet, Tennessee. “I don’t look at these situations in life as being downers.” Boeing flew its Starliner capsule home empty in September, and NASA moved Wilmore and Williams to a SpaceX flight not due back until late February. Two other astronauts were bumped to make room and to keep to a six-month schedule for crew rotations. Like other station crews, Wilmore and Williams trained for spacewalks and any unexpected situations that might arise. “When the crews go up, they know they could be there for up to a year,” said NASA Associate Administrator Jim Free. NASA astronaut Frank Rubio found that out the hard way when the Russian Space Agency had to rush up a replacement capsule for him and two cosmonauts in 2023, pushing their six-month mission to just past a year. Boeing said this week that input from Wilmore and Williams has been “invaluable" in the ongoing inquiry of what went wrong. The company said in a statement that it is preparing for Starliner's next flight but declined comment on when it might launch again. NASA also has high praise for the pair. “Whether it was luck or whether it was selection, they were great folks to have for this mission,” NASA's chief health and medical officer, Dr. JD Polk, said during an interview with The Associated Press. On top of everything else, Williams, 59, has had to deal with “rumors,” as she calls them, of serious weight loss. She insists her weight is the same as it was on launch day, which Polk confirms. During Wednesday's student chat, Williams said she didn't have much of an appetite when she first arrived in space. But now she's “super hungry” and eating three meals a day plus snacks, while logging the required two hours of daily exercise. Williams, a distance runner, uses the space station treadmill to support races in her home state. She competed in Cape Cod’s 7-mile Falmouth Road Race in August. She ran the 2007 Boston Marathon up there as well. She has a New England Patriots shirt with her for game days, as well as a Red Sox spring training shirt. “Hopefully I’ll be home before that happens -- but you never know,” she said in November. Husband Michael Williams, a retired federal marshal and former Navy aviator, is caring for their dogs back home in Houston. As for Wilmore, 61, he's missing his younger daughter's senior year in high school and his older daughter's theater productions in college. “We can’t deny that being unexpectedly separated, especially during the holidays when the entire family gets together, brings increased yearnings to share the time and events together,” his wife, Deanna Wilmore, told the AP in a text this week. Her husband “has it worse than us” since he's confined to the space station and can only connect via video for short periods. “We are certainly looking forward to February!!” she wrote. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
None
By Stephen Beech via SWNS Cleaning surfaces every two hours at airports cuts potentially deadly norovirus infections by 83%, according to a new study. Researchers found that airport restaurants had the highest risk of norovirus transmission . But frequently disinfecting surfaces, mask-wearing and antimicrobial surface coatings at the transport hubs can all help prevent the highly contagious illness - also known as the winter vomiting bug - from spreading, say scientists. Study author Professor Nan Zhang, of the Beijing University of Technology in China, said: "Norovirus causes severe vomiting and diarrhea and is responsible for about 685 million cases and 200,000 deaths each year. "The virus is primarily transmitted through surfaces and outbreaks during air travel are especially common, due to the large number of public surfaces in airports." To investigate the risk of norovirus infection from surfaces among passengers in different zones of the airport, the research team collected real touch data from 21.3 hours of video, which captured almost 26,000 touches. They developed a model of surface transmission and simulated the risk of infection from norovirus and the effectiveness of various interventions in different airport areas. Zhang said: "The touch data showed that, without any interventions, restaurants at airports had the highest risk of norovirus transmission, with approximately 4.6 out of 51,494 travelers infected. "Disinfecting public surfaces every two hours reduced the risk of norovirus infection per visit to the airport by 83.2%. "In contrast, handwashing every two hours reduced the risk by only 2%, and mask-wearing 50% of the time reduced risk by 48.0%, because masks stop people from touching their face. "Furthermore, using antimicrobial copper or copper-nickel alloy coatings for most public surfaces lowered the infection risk by 15.9% to 99.2%." He says the study, published in the journal PLOS Computational Biology , provides "crucial" insights for developing infection prevention and control strategies specifically tailored for norovirus within airport environments. Zhang noted that the data for the study was collected during the COVID-19 pandemic , so surface-touching behaviors may have been different from normal. But he said that, overall, the simulated results indicated that public surface disinfection, mask-wearing wearing and the use of antimicrobial surfaces are effective ways of controlling the spread of norovirus via surfaces. Zhang added: "Regular surface infection is much more effective than regular handwashing for blocking norovirus transmission via fomite route in airports."Opinion: B.C.’s business disadvantage about to get worse
Jack Butland backs Rangers star to shine against Celtic in Hampden final after lighting up Europa League Nico Raskin was awarded player of the match in midweek draw with Spurs Midfielder has impressed this season on his return from injury Butland believes he could play a key role in Sunday's Premier Sports Cup final By STEPHEN MCGOWAN Published: 22:30, 13 December 2024 | Updated: 22:30, 13 December 2024 e-mail 52 shares View comments In the post-match melee of the game against Tottenham , Rangers goalkeeper Jack Butland made a beeline for the player of the match. Plagued by injuries for much of his two years in Glasgow, Nico Raskin embodies the recent improvement at Ibrox. With every game, with every victory, he grows a little stronger. Against Ange Postecoglou ’s expensively assembled English Premier League outfit, the Belgian had his best game in a Rangers jersey to date. Replicate the same performance against Celtic at Hampden tomorrow and Rangers have a chance of nullifying their oldest rivals to retain the Premier Sports Cup. ‘I said it to him after the game, it’s one of the best — if not the best — I’ve ever seen him play,’ revealed Butland. ‘So hopefully he can top that on the weekend. ‘I’m really, really pleased for him. He’s been brilliant, as were so many the other night. I thought Dio (Mohamed Diomande) was fantastic as well. Hamza (Igamane), the way he led the line. Tav was brilliant. So was Jefte. Jack Butland has hailed the performances of Nico Raskin during Rangers' recent run Raskin was a standout performer against Tottenham in the Europa League midweek Hamza Igamane put Rangers in front in the second half against the English giants at Ibrox ‘They’re dealing with some real attacking threats and they were top. So Nico was brilliant, as was everyone else. We need more of that on the weekend.’ For Butland, progress at Rangers has always been a marathon and not a sprint. A test of endurance — for fans as much as players — with hurdles and obstacles to be overcome. The first half of the race was a dogged test of staying power, the team gasping for breath after a 1-1 draw with Dundee United almost broke them. A day when Philippe Clement’s position looked untenable, promises of jam tomorrow rang increasingly hollow. Trailing to a Sam Dalby goal and booed from the pitch by an irate fanbase at half-time, a frank exchange of views provoked a second-half improvement and, in hindsight, the point secured by Vaclav Cerny’s equaliser can be viewed as a turning point. Evidence of unexpected powers of endurance. A thumping win over Nice in France announced the arrival of Igamane as a Rangers starter. Marrying the results in Europe with some overdue consistency on home soil, victories over St Johnstone and Ross County followed, before a six-goal thrashing of Kilmarnock. A Europa League point against a star-studded Tottenham side altered the narrative further. Rangers have a second wind now, with the final hurdle a long overdue win over Celtic. Written off all of two weeks ago, Butland emits a wry smile at the change of fortunes. Phillipe Clement hopes to earn his first win over Celtic in six attempts this weekend ‘That’s what people tend to do with this club and hopefully we continue to disappoint people and get back to where we should be,’ said the former England No 1. ‘It’s a long journey. There’s still things that we need to improve, but we’re getting there and the work ethic and desire in the group and around the club is to be successful. We really want that. ‘There were things that we didn’t do in the first half of that Dundee United game. It wasn’t about the goal that we conceded. It was about what we didn’t do and the things that we just didn’t quite get on the same page with in the first half. ‘The second half of that game, we had it and we created enough chances to win two or three games. But sometimes things will go your way and sometimes it doesn’t. It didn’t that day and we got punished for it. ‘In recent weeks we’ve learned from that and really taken the game to people, which is what we need to do.’ The aggressive intent and intensity was apparent from the start against Tottenham. Sensing the vulnerability of a team with one win from their last seven, Nedim Bajrami forced Fraser Forster into a stunning fingertip save. But for the former Celtic keeper — a thorn in Rangers’ side in the League Cup final of 2019 — Clement’s team would have overcome the loss of Dejan Kulusevski’s late equaliser to claim a famous victory. In very Cyriel Dessers fashion, the substitute did everything right during a mazy solo run late in the game before Forster denied the home side a win for the ages. Celtic's Adam Idah scored the winner against Butland in last year's Scottish Cup Final The keeper was the only Spurs player to earn pass marks and that spoke volumes for the Rangers performance. There was no time to bask in the afterglow. While Celtic flew home from Zagreb to rest and recuperate ahead of Hampden, Rangers were left with precious little time to do the same. Despite dropped points in the league against Celtic, Dundee United, Hearts, Kilmarnock and Aberdeen, none of the slips followed a Thursday night game in Europe. Butland added: ‘We’ve done Thursday-Sunday and Wednesday-Saturday for the last 18 months since I’ve been here and long before that. So, there’s no excuse on that front.’ Share or comment on this article: Jack Butland backs Rangers star to shine against Celtic in Hampden final after lighting up Europa League e-mail 52 shares Add commentSAN FRANCISCO--(BUSINESS WIRE)--Dec 5, 2024-- All Remote – GitLab Inc. (NASDAQ: GTLB), the most comprehensive AI-powered DevSecOps platform, today reported financial results for its third quarter fiscal year 2025, ended October 31, 2024. “GitLab’s growth at scale is a testament to the demand for a platform approach to software development,” said Sid Sijbrandij, co-founder and executive chair of the board of directors, GitLab Inc. “Our end-to-end DevSecOps platform addresses our customers’ need to accelerate the pace of software development to remain competitive, innovate faster, and ship software more securely.” In a separate press release issued today, December 5, 2024, the company announced Bill Staples was named CEO and a member of the board of directors effective today. Staples succeeds co-founder and CEO Sid Sijbrandij, who is stepping down from his day-to-day role to focus on his health. Sijbrandij will transition to executive chair of the GitLab board of directors. The announcement can be found at https://ir.gitlab.com/ . “We delivered record non-GAAP operating margins as our third quarter fiscal year 2025 revenue reached $196 million dollars, an increase of 31% year-over-year,” said Brian Robins, GitLab chief financial officer. “I am very pleased with our results and the team’s execution as we continue to deliver against our commitment to responsible growth.” Third Quarter Fiscal Year 2025 Financial Highlights (in millions, except per share data and percentages) : Q3 FY 2025 Q3 FY 2024 Y/Y Change Revenue $ 196.0 $ 149.7 31 % GAAP Gross margin 89 % 90 % Non-GAAP Gross margin 91 % 91 % GAAP Operating margin (15 )% (27 )% Non-GAAP Operating margin 13 % 3 % GAAP Operating loss $ (28.7 ) $ (40.3 ) $ 11.6 Non-GAAP Operating income $ 25.9 $ 4.7 $ 21.2 GAAP Net Income (loss) attributable to GitLab $ 29.6 $ (285.2 ) $ 314.8 Non-GAAP Net income attributable to GitLab $ 39.1 $ 14.4 $ 24.7 GAAP Net income (loss) per share attributable to GitLab, basic $ 0.18 $ (1.84 ) $ 2.02 GAAP Net income (loss) per share attributable to GitLab, diluted $ 0.18 $ (1.84 ) $ 2.02 Non-GAAP Net income per share attributable to GitLab, basic $ 0.24 $ 0.09 $ 0.15 Non-GAAP Net income per share attributable to GitLab, diluted $ 0.23 $ 0.09 $ 0.14 GAAP net cash used in operating activities $ (177.0 ) $ (6.0 ) $ (171.0 ) Non-GAAP adjusted free cash flow $ 9.7 $ (6.7 ) $ 16.4 A reconciliation between GAAP and non-GAAP financial measures is contained in this release under the section titled “Non-GAAP Financial Measures.” Additional Financial Highlights: Customers with more than $5,000 of ARR reached 9,519, an increase of 16% year-over-year. Customers with more than $100,000 of ARR reached 1,144, an increase of 31% year-over-year. Dollar-Based Net Retention Rate was 124%. Total RPO grew 48% year-over-year to $811.8 million, while cRPO grew 39% to $515.2 million. Business Highlights: Recognized as a Leader in the Gartner® Magic QuadrantTM for DevOps Platforms for the second consecutive year. Announced an integrated offering with AWS that brings together GitLab Duo and Amazon Q. Together, GitLab Duo and Amazon Q provide a seamless AI-powered developer experience that combines DevSecOps workflows and AWS environments to help organizations ship secure software faster. Announced the general availability of Advanced SAST for GitLab Ultimate customers, leveraging technology acquired with Oxeye, for more accurate vulnerability detections in first-party code. Fourth Quarter and Fiscal Year 2025 Financial Outlook For the fourth quarter and fiscal year 2025, GitLab Inc. expects ( in millions, except share and per share data) : Q4 FY 2025 Guidance FY 2025 Guidance Revenue $205.0 - $206.0 $753 - $754 Non-GAAP operating income $28.0 - $29.0 $69 - $70 Non-GAAP diluted net income per share assuming approximately 170 million and 168 million weighted average shares outstanding during Q4 FY 2025 and FY 2025, respectively. $0.22 - $0.23 $0.63 - $0.64 These statements are forward-looking and actual results may differ materially as a result of many factors. Refer to the Forward-Looking Statements safe harbor below for information on the factors that could cause our actual results to differ materially from these forward-looking statements. A reconciliation of GAAP to non-GAAP financial measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below in Non-GAAP Financial Measures. We have not provided the most directly comparable GAAP financial guidance measures because certain items are out of our control or cannot be reasonably predicted. Accordingly, a reconciliation of non-GAAP guidance for operating income (loss) and net income (loss) per share to the corresponding GAAP measures is not available. Conference Call Information GitLab will host a conference call today, December 5, 2024, at 1:30 p.m. (PT) / 4:30 p.m. (ET) to discuss its third quarter fiscal year 2025 financial results and its guidance for the fourth quarter and fiscal year 2025. Interested parties may register for the call in advance by visiting https://bit.ly/3Ul8cwM . A live webcast of this conference call will be available on GitLab’s investor relations website ( ir.gitlab.com ), and a replay will also be archived on the website for one year. About GitLab GitLab is the most comprehensive AI-powered DevSecOps platform for software innovation. GitLab enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. More than 40 million registered users and more than 50% of the Fortune 100 trust GitLab to ship better, more secure software faster. Non-GAAP Financial Measures GitLab believes non-GAAP measures are useful in evaluating its operating performance. GitLab uses this supplemental information to evaluate its ongoing operations and for internal planning and forecasting purposes. GitLab believes that non-GAAP financial information, when taken collectively with its GAAP financial information, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Reconciliations of non-GAAP financial measures to the most directly comparable financial results as determined in accordance with GAAP are included at the end of this press release following the accompanying financial data. We define non-GAAP financial measures as GAAP measures, excluding certain items such as stock-based compensation expense, amortization of acquired intangible assets, foreign exchange (gain) loss, equity method investment loss and impairment, acquisition related expenses, changes in the fair value of acquisition related contingent consideration, charitable donation of common stock, restructuring charges, a non-recurring income tax adjustment related to bilateral advance pricing agreement (“BAPA”) negotiations, and other expenses that the Company believes are not indicative of its ongoing operations. Shares used for net income per share on a non-GAAP basis include incremental dilutive shares related to restricted stock units, options, and shares issuable under GitLab Inc.’s 2021 Employee Stock Purchase Plan that are anti-dilutive on a GAAP basis. A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business. Adjusted Free Cash Flow Adjusted free cash flow is a non-GAAP financial measure that we calculate as net cash provided by operating activities less cash used for purchases of property and equipment, plus any non-recurring income tax payments related to BAPA. We believe that adjusted free cash flow is a useful indicator of liquidity that provides information to management and investors about the amount of cash generated from our operations that, after the investments in property and equipment and any non-recurring income tax payments related to BAPA, can be used for strategic initiatives, including investing in our business, and strengthening our financial position. One limitation of adjusted free cash flow is that it does not reflect our future contractual commitments. Additionally, adjusted free cash flow does not represent the total increase or decrease in our cash balance for a given period. Forward-Looking Statements This press release and the accompanying earnings call contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Although we believe that the expectations reflected in the forward-looking statements contained in this release and the accompanying earnings call are reasonable, they are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results or outcomes to be materially different from any future results or outcomes expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions, and other factors include, but are not limited to the following: our ability to effectively manage our growth; our revenue growth rate in the future; our ability to achieve and sustain profitability, our business, financial condition, and operating results; security and privacy breaches; intense competition in our markets and loss of market share to our competitors; our ability to respond to rapid technological changes; the market for our services may not grow; a decline in our customer renewals and expansions; fluctuations in our operating results; our incorporation of artificial intelligence features into our products; our transparency; our publicly available company Handbook; customers staying on our free self-managed or SaaS product offering; our ability to accurately predict the long-term rate of customer subscription renewals or adoption, or the impact of these renewals and adoption; our hiring model; the effects of ongoing armed conflict in different regions of the world on our business; and general economic conditions (including changes in interest rates, inflation, uncertainty of the federal budget, increased volatility in the capital markets, and instability in the global banking sector) and slow or negative growth of our markets. Further information on these and additional risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those included in or contemplated by the forward-looking statements contained in this release are included under the caption “Risk Factors” and elsewhere in the filings and reports we make with the Securities and Exchange Commission. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law. Operating Metrics Annual Recurring Revenue (“ARR”): We define annual recurring revenue as the annual run-rate revenue of subscription agreements, including our self-managed and SaaS offerings but excluding professional services, from all customers as measured on the last day of a given month. We calculate ARR by taking the monthly recurring revenue (“MRR”) and multiplying it by 12. MRR for each month is calculated by aggregating, for all customers during that month, monthly revenue from committed contractual amounts of subscriptions, including our self-managed license, self-managed subscription, and SaaS subscription offerings but excluding professional services. Dollar-Based Net Retention Rate: We calculate Dollar-Based Net Retention Rate as of a period end by starting with our customers as of the 12 months prior to such period end (“Prior Period ARR”). We then calculate the ARR from these customers as of the current period end (“Current Period ARR”). The calculation of Current Period ARR includes any upsells, price adjustments, user growth within a customer, contraction, and attrition. We then divide the total Current Period ARR by the total Prior Period ARR to arrive at the Dollar-Based Net Retention Rate. GitLab Inc. Condensed Consolidated Balance Sheets (in thousands, except per share data) (unaudited) October 31, 2024 (1) January 31, 2024 (1) ASSETS CURRENT ASSETS: Cash and cash equivalents $ 176,632 $ 287,996 Short-term investments 740,340 748,289 Accounts receivable, net of allowance for doubtful accounts of $891 and $673 as of October 31, 2024 and January 31, 2024, respectively 197,555 166,731 Deferred contract acquisition costs, current 34,518 32,300 Prepaid expenses and other current assets 43,120 45,601 Total current assets 1,192,165 1,280,917 Property and equipment, net 3,563 2,954 Operating lease right-of-use assets 444 405 Goodwill 16,131 8,145 Intangible assets, net 19,536 1,733 Deferred contract acquisition costs, non-current 17,248 19,317 Other non-current assets 3,552 4,390 TOTAL ASSETS $ 1,252,639 $ 1,317,861 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES: Accounts payable $ 2,224 $ 1,738 Accrued expenses and other current liabilities 51,821 286,178 Accrued compensation and benefits 27,274 35,809 Deferred revenue, current 383,183 338,348 Total current liabilities 464,502 662,073 Deferred revenue, non-current 14,138 23,794 Other non-current liabilities 3,776 14,060 TOTAL LIABILITIES 482,416 699,927 STOCKHOLDERS’ EQUITY: Preferred stock, $0.0000025 par value; 50,000 shares authorized as of October 31, 2024 and January 31, 2024; no shares issued and outstanding as of October 31, 2024 and January 31, 2024 — — Class A Common stock, $0.0000025 par value; 1,500,000 shares authorized as of October 31, 2024 and January 31, 2024; 140,528 and 114,670 shares issued and outstanding as of October 31, 2024 and January 31, 2024, respectively — — Class B Common stock, $0.0000025 par value; 250,000 shares authorized as of October 31, 2024 and January 31, 2024; 21,555 and 42,887 shares issued and outstanding as of October 31, 2024 and January 31, 2024, respectively — — Additional paid-in capital 1,891,653 1,718,661 Accumulated deficit (1,161,952 ) (1,149,822 ) Accumulated other comprehensive income (loss) (4,996 ) 2,335 Total GitLab stockholders’ equity 724,705 571,174 Noncontrolling interests 45,518 46,760 TOTAL STOCKHOLDERS’ EQUITY 770,223 617,934 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 1,252,639 $ 1,317,861 (1) As of October 31, 2024 and January 31, 2024, the consolidated balance sheet includes assets of the consolidated variable interest entity, GitLab Information Technology (Hubei) Co., LTD (“JiHu”), of $43.4 million and $47.6 million, respectively, and liabilities of $6.1 million for each period presented. The assets of JiHu can be used only to settle obligations of JiHu and creditors of JiHu do not have recourse against the general credit of GitLab Inc. GitLab Inc. Condensed Consolidated Statements of Operations (in thousands, except per share data) (unaudited) Three Months Ended October 31, Nine Months Ended October 31, 2024 2023 2024 2023 Revenue: Subscription—self-managed and SaaS $ 175,257 $ 130,993 $ 489,617 $ 364,280 License—self-managed and other 20,790 18,675 58,201 51,847 Total revenue 196,047 149,668 547,818 416,127 Cost of revenue: Subscription—self-managed and SaaS 17,170 11,559 47,639 33,321 License—self-managed and other 4,955 3,525 14,632 10,398 Total cost of revenue 22,125 15,084 62,271 43,719 Gross profit 173,922 134,584 485,547 372,408 Operating expenses: Sales and marketing 95,340 86,978 285,542 265,631 Research and development 61,354 49,058 176,767 148,452 General and administrative 45,960 38,815 146,615 110,882 Total operating expenses 202,654 174,851 608,924 524,965 Loss from operations (28,732 ) (40,267 ) (123,377 ) (152,557 ) Interest income 12,586 10,874 37,443 27,301 Other income (expense), net 4,992 569 5,457 (508 ) Loss before income taxes and loss from equity method investment (11,154 ) (28,824 ) (80,477 ) (125,764 ) Loss from equity method investment, net of tax — (743 ) — (2,408 ) Provision for (benefit from) income taxes (39,421 ) 256,788 (66,131 ) 262,290 Net income (loss) $ 28,267 $ (286,355 ) $ (14,346 ) $ (390,462 ) Net loss attributable to noncontrolling interest (1,298 ) (1,197 ) (2,216 ) (2,755 ) Net income (loss) attributable to GitLab $ 29,565 $ (285,158 ) $ (12,130 ) $ (387,707 ) Net income (loss) per share attributable to GitLab Class A and Class B common stockholders: Basic $ 0.18 $ (1.84 ) $ (0.08 ) $ (2.53 ) Diluted $ 0.18 $ (1.84 ) $ (0.08 ) $ (2.53 ) Weighted-average shares used to compute net income (loss) per share attributable to GitLab Class A and Class B common stockholders: Basic 161,317 155,123 159,756 153,504 Diluted 167,436 155,123 159,756 153,504 GitLab Inc. Condensed Consolidated Statements of Cash Flows (in thousands) (unaudited) Three Months Ended October 31, Nine Months Ended October 31, 2024 2023 2024 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Net income (loss), including amounts attributable to noncontrolling interest $ 28,267 $ (286,355 ) $ (14,346 ) $ (390,462 ) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Stock-based compensation expense 48,042 41,334 139,263 120,032 Change in fair value of acquisition related contingent consideration — — 3,750 — Charitable donation of common stock 2,957 2,675 8,871 8,025 Amortization of intangible assets 2,511 521 5,931 1,646 Depreciation expense 680 1,123 2,361 3,329 Amortization of deferred contract acquisition costs 12,704 10,447 35,650 31,066 Loss from equity method investment — 940 — 3,048 Net amortization of premiums or discounts on short-term investments (3,792 ) (5,867 ) (12,933 ) (14,361 ) Unrealized foreign exchange loss (gain), net (5,184 ) (573 ) (5,442 ) 252 Other non-cash expense, net 467 420 768 317 Changes in assets and liabilities: Accounts receivable (32,883 ) (30,572 ) (31,658 ) (5,291 ) Prepaid expenses and other current assets (10,773 ) (3,935 ) 2,498 (8,183 ) Deferred contract acquisition costs (14,751 ) (13,623 ) (35,706 ) (31,760 ) Other non-current assets 1,348 (453 ) 851 (1,174 ) Accounts payable (1,317 ) 799 33 (224 ) Accrued expenses and other current liabilities (220,071 ) 244,674 (241,704 ) 245,857 Accrued compensation and benefits (1,913 ) 231 (8,815 ) 2,842 Deferred revenue 19,665 14,270 34,503 29,158 Other non-current liabilities (2,985 ) 17,983 (11,068 ) 16,070 Net cash provided by (used in) operating activities (177,028 ) (5,961 ) (127,193 ) 10,187 CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of short-term investments (240,136 ) (238,680 ) (503,394 ) (573,676 ) Proceeds from maturities of short-term investments 148,763 253,995 524,862 526,979 Purchases of property and equipment (1,057 ) (736 ) (2,608 ) (1,269 ) Payments for business combination, net of cash acquired — — (20,210 ) — Payments for asset acquisition (346 ) — (7,660 ) — Escrow payment related to business combination, after acquisition date — — — (2,500 ) Other investing activities — — 457 — Net cash provided by (used in) investing activities (92,776 ) 14,579 (8,553 ) (50,466 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from the issuance of common stock upon exercise of stock options, including early exercises, net of repurchases 7,822 4,715 17,895 22,492 Issuance of common stock under employee stock purchase plan — — 7,932 7,751 Settlement of acquisition related contingent cash consideration (4,900 ) — (4,900 ) — Net cash provided by financing activities 2,922 4,715 20,927 30,243 Impact of foreign exchange on cash and cash equivalents 4,898 (1,249 ) 3,455 (2,557 ) Net decrease in cash and cash equivalents (261,984 ) 12,084 (111,364 ) (12,593 ) Cash and cash equivalents at beginning of period 438,616 273,225 287,996 297,902 Cash and cash equivalents at end of period $ 176,632 $ 285,309 $ 176,632 $ 285,309 GitLab Inc. Reconciliation of GAAP to Non-GAAP (in thousands, except per share data) (unaudited) Three Months Ended October 31, Nine Months Ended October 31, 2024 2023 2024 2023 Gross profit on GAAP basis $ 173,922 $ 134,584 $ 485,547 $ 372,408 Gross margin on GAAP basis 89 % 90 % 89 % 89 % Stock-based compensation expense 1,993 1,648 5,924 4,760 Amortization of acquired intangibles 2,511 521 5,931 1,546 Restructuring charges — — — 463 Gross profit on non-GAAP basis $ 178,426 $ 136,753 $ 497,402 $ 379,177 Gross margin on non-GAAP basis 91 % 91 % 91 % 91 % Sales and marketing on GAAP basis $ 95,340 $ 86,978 $ 285,542 $ 265,631 Stock-based compensation expense (17,012 ) (16,523 ) (54,290 ) (51,582 ) Restructuring charges (130 ) 54 (1,126 ) (3,623 ) Sales and marketing on non-GAAP basis $ 78,198 $ 70,509 $ 230,126 $ 210,426 Research and development on GAAP basis $ 61,354 $ 49,058 $ 176,767 $ 148,452 Stock-based compensation expense (14,384 ) (12,738 ) (42,834 ) (36,917 ) Restructuring charges — (72 ) (393 ) (2,119 ) Research and development on non-GAAP basis $ 46,970 $ 36,248 $ 133,540 $ 109,416 General and administrative on GAAP basis $ 45,960 $ 38,815 $ 146,615 $ 110,882 Stock-based compensation expense (14,653 ) (10,425 ) (36,215 ) (26,773 ) Amortization of acquired intangibles — — — (100 ) Restructuring charges 11 4 (377 ) (1,634 ) Charitable donation of common stock (2,957 ) (2,675 ) (8,871 ) (8,025 ) Changes in the fair value of acquisition related contingent consideration — — (3,750 ) — Acquisition related expenses (140 ) — (2,849 ) — Other non-recurring charges (872 ) (413 ) (1,084 ) (413 ) General and administrative on non-GAAP basis $ 27,349 $ 25,306 $ 93,469 $ 73,937 Loss from operations on GAAP basis $ (28,732 ) $ (40,267 ) $ (123,377 ) $ (152,557 ) Stock-based compensation expense 48,042 41,334 139,263 120,032 Amortization of acquired intangibles 2,511 521 5,931 1,646 Restructuring charges 119 14 1,896 7,839 Charitable donation of common stock 2,957 2,675 8,871 8,025 Changes in the fair value of acquisition related contingent consideration — — 3,750 — Acquisition related expenses 140 — 2,849 — Other non-recurring charges 872 413 1,084 413 Income (loss) from operations on non-GAAP basis $ 25,909 $ 4,690 $ 40,267 $ (14,602 ) Other income (expense), net on GAAP basis $ 4,992 $ 569 $ 5,457 $ (508 ) Foreign exchange gains (losses), net (5,096 ) (488 ) (5,326 ) 506 Other income (expense), net on non-GAAP basis $ (104 ) $ 81 $ 131 $ (2 ) Net income (loss) attributable to GitLab common stockholders on GAAP basis $ 29,565 $ (285,158 ) $ (12,130 ) $ (387,707 ) Stock-based compensation expense 48,042 41,334 139,263 120,032 Amortization of acquired intangibles 2,511 521 5,931 1,646 Restructuring charges 119 14 1,896 7,839 Charitable donation of common stock 2,957 2,675 8,871 8,025 Changes in the fair value of acquisition related contingent consideration — — 3,750 — Acquisition related expenses 140 — 2,849 — Loss from equity method investment, net of tax — 743 — 2,408 Foreign exchange gains (losses), net (5,096 ) (488 ) (5,326 ) 506 Income tax adjustment (39,965 ) 254,392 (78,047 ) 254,392 Other non-recurring charges 872 413 1,084 413 Net income attributable to GitLab common stockholders on non-GAAP basis $ 39,145 $ 14,446 $ 68,141 $ 7,554 GAAP net income (loss) per share, basic $ 0.18 $ (1.84 ) $ (0.08 ) $ (2.53 ) GAAP net income (loss) per share, diluted $ 0.18 $ (1.84 ) $ (0.08 ) $ (2.53 ) Non-GAAP net income per share, basic $ 0.24 $ 0.09 $ 0.43 $ 0.05 Non-GAAP net income per share, diluted $ 0.23 $ 0.09 $ 0.41 $ 0.05 Shares used in per share calculation - basic on GAAP basis 161,317 155,123 159,756 153,504 Effect of dilutive securities 6,119 7,671 7,637 7,774 Shares used in per share calculation - diluted on non-GAAP basis 167,436 162,794 167,393 161,278 GitLab Inc. Reconciliation of GAAP Cash Flow from Operating Activities to Adjusted Free Cash Flow (in thousands) (unaudited) Three Months Ended October 31, Nine Months Ended October 31, 2024 2023 2024 2023 Computation of adjusted free cash flow GAAP net cash provided by (used in) operating activities $ (177,028 ) $ (5,961 ) $ (127,193 ) $ 10,187 Less: Purchases of property and equipment (1,057 ) (736 ) (2,608 ) (1,269 ) Add: Income tax payments related to BAPA 187,735 — 187,735 — Non-GAAP adjusted free cash flow $ 9,650 $ (6,697 ) $ 57,934 $ 8,918 View source version on businesswire.com : https://www.businesswire.com/news/home/20241205686308/en/ CONTACT: Media Contact: Lisa Boughner VP, Global Communications GitLab Inc. press@gitlab.com Investor Contact: Kelsey Turcotte VP, Investor Relations GitLab Inc. ir@gitlab.com KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: DATA MANAGEMENT SECURITY APPS/APPLICATIONS TECHNOLOGY SOFTWARE ARTIFICIAL INTELLIGENCE SOURCE: GitLab Inc. Copyright Business Wire 2024. PUB: 12/05/2024 04:06 PM/DISC: 12/05/2024 04:05 PM http://www.businesswire.com/news/home/20241205686308/enInterDigital Declares Regular Quarterly Cash Dividend
// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC , Dec. 13, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (" BioVaxys " or the " Company ") is pleased to announce that it has closed the first tranche (the " First Tranche ") of its previously announced non-brokered private placement (the " Private Placement ") with the issuance of 2,200,000 units (the " Units ") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $110,000 . Each Unit consist of one (1) common share in the capital of the Company (each, a " Share ") and one (1) whole Share purchase warrant (each, a " Warrant "), whereby each Warrant is convertible into one additional Share at an exercise price of $0.15 until December 13, 2026 , being the date that is 24 months from the date of issue. The Company intends to use the net proceeds of the First Tranche for working capital. No finder's fees were paid in connection with the First Tranche. All securities issued pursuant to the First Tranche are subject to a statutory hold period expiring April 14, 2025 , being the date that is four months and one day from the date of issuance in accordance with applicable securities legislation In addition, the Company announces that it has entered into a debt settlement agreement with an arm's-length consultant of the Company to settle an aggregate of $500,000 in debt owed to the consultant by issuing 5,000,000 Shares at a deemed price of $0.10 per Share (the " Debt Settlement "). The board of directors of the Company has determined that it is in the best interests of the Company to settle the outstanding debt through the issuance of Shares in order to preserve the Company's cash for working capital purposes. All securities proposed to be issued pursuant to the Debt Settlement will be subject to a statutory hold period of four months from the date of issuance in accordance with applicable securities legislation. Closing of the Debt Settlement is conditional upon a number of conditions, including receipt of all applicable corporate and regulatory approvals, including the acceptance of the Canadian Securities Exchange. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States . The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933 , as amended (the " U.S. Securities Act "), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( www.biovaxys.com ), a company registered in British Columbia, Canada , is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPXTM immune-educating technology platform and it's HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. DPXTM is a patented antigen delivery platform that can incorporate a range of bioactive molecules to produce targeted, long-lasting immune responses enabled by various formulated components. The DPX platform facilitates antigen delivery to regional lymph nodes and has been demonstrated to induce robust and durable T cell and B cell responses in pre-clinical and clinical studies for both cancer and infectious disease. BioVaxys' common shares are listed on the Canadian Securities Exchange under the stock symbol "BIOV", on the Frankfurt Bourse (FRA: 5LB), and quoted in the US on the OTC Markets. For more information, visit www.biovaxys.com and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed " James Passin " James Passin , Chief Executive Officer Phone: +1 740 358 0555 Cautionary Statements Regarding Forward Looking Information This news release includes certain "forward-looking information" and "forward-looking statements" (collectively " forward-looking statements ") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, the statements relating to the Private Placement and the Debt Settlement, including the expected use of proceeds from the Private Placement and related issuance of the Shares for the Debt Settlement, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the impact of any changes that may affect the anticipated use of proceeds from the Private Placement and the ability of the Company to obtain the necessary approvals to proceed with the Debt Settlement. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws. The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this press release and does not accept responsibility for the adequacy or accuracy of this release. Logo - https://mma.prnewswire.com/media/2415135/5078410/BioVaxys_Technology_Corp_Logo.jpgTalks are under way to return members of the Bali Nine drug smuggling ring to Australia, the federal trade minister has confirmed while asserting they would continue to serve their sentences and not be released. Login or signup to continue reading The Australians were arrested in 2005 for attempting to smuggle heroin out of the Indonesian resort island. Five remaining members have been serving life sentences in the country for their involvement. Trade Minister Don Farrell said discussions were ongoing but confirmed the Prime Minister Anthony Albanese had advocated on behalf of the Australians. The prisoners would continue to serve their sentences in Australia under the proposal, he told Sky News on Sunday. "The proposal isn't, as I understand it, to release these people," Senator Farrell said. "They would continue to serve their sentence, except they're serving them in Australia." Mr Albanese raised the prisoner issue during a meeting with Indonesia's President Prabowo Subianto on the sidelines of the APEC Summit in Peru, Australian Assistant Treasurer Stephen Jones told reporters on Saturday. Under the deal, Jakarta would seek the repatriation of Indonesian prisoners held in Australia, the country's Law Minister Supratman Andi Agtas told Reuters on Saturday. Jakarta has no set procedures regarding international prisoner transfers but would work on the matter as soon as possible, Supratman said, stressing the counterpart country must recognise Indonesia's judicial process. "This is important to maintain a good relationship with friendly countries but this is also in our interest because we have prisoners abroad," he said. Deputy opposition leader Sussan Ley urged the prime minister to provide Australians with more information about the deal. "Let's be clear, in the first instance, these individuals, Australians, were part of a heroin-smuggling ring to bring back into Australia, in excess of eight kilos of heroin," she told Sky News on Sunday. "Drug offences are some of the worst offences our society sees because of the devastating consequences on people, including death." She called on the prime minister to confirm how the deal had been brokered, whether there would be a cost to the taxpayer, and whether they would continue to serve their full prison sentences in Australia. " And if not, why not?" she said. Bali Nine members Scott Rush, Matthew Norman, Si-Yi Chen, Martin Stephens and Michael Czugaj are serving life sentences in Indonesia for their involvement. Another member of the nine, Renae Lawrence, was released from prison in 2018 while Tan Duc Than Nguyen died of cancer the same year. The execution of two of the group's ringleaders, Andrew Chan and Myuran Sukumaran, in 2015 caused a diplomatic rupture between Australia and Indonesia. Australia recalled its ambassador in protest. with Reuters Australian Associated Press DAILY Today's top stories curated by our news team. Also includes evening update. WEEKDAYS Grab a quick bite of today's latest news from around the region and the nation. WEEKLY The latest news, results & expert analysis. WEEKDAYS Catch up on the news of the day and unwind with great reading for your evening. WEEKLY Get the editor's insights: what's happening & why it matters. WEEKLY Love footy? We've got all the action covered. WEEKLY Every Saturday and Tuesday, explore destinations deals, tips & travel writing to transport you around the globe. WEEKLY Get the latest property and development news here. WEEKLY Going out or staying in? Find out what's on. WEEKDAYS Sharp. Close to the ground. Digging deep. Your weekday morning newsletter on national affairs, politics and more. WEEKLY Follow the Newcastle Knights in the NRL? Don't miss your weekly Knights update. TWICE WEEKLY Your essential national news digest: all the big issues on Wednesday and great reading every Saturday. WEEKLY Get news, reviews and expert insights every Thursday from CarExpert, ACM's exclusive motoring partner. TWICE WEEKLY Get real, Australia! Let the ACM network's editors and journalists bring you news and views from all over. AS IT HAPPENS Be the first to know when news breaks. DAILY Your digital replica of Today's Paper. Ready to read from 5am! DAILY Test your skills with interactive crosswords, sudoku & trivia. Fresh daily!
Another one of those who had their sentences commuted by President Joe Biden was notorious University of Miami booster and convicted Ponzi schemer Nevin Shapiro. Shapiro was convicted of a Ponzi scheme that raked in nearly a billion dollars in 2010 after he bilked thousands of people who invested in his fake company, Capital Investments. His crimes included creating fake documents purportedly showing how CI made tens of millions a year from owning and operating a nonexistent grocery wholesale business. He was convicted and handed a 20-year prison sentence in 2010. Meanwhile, Shapiro was spending $400,000 for floor seats to watch the Miami Heat, $26,000 a month on rent for his home in Miami Beach, a $1.5 million yacht, expensive cars, and other luxuries. He reportedly hobnobbed with NBA players such as Shaquille O’Neal, Dwyane Wade, and Kevin Garnett. Shapiro also worked closely with the University of Miami, pledging $150,000 to help the school build a student lounge in his name. The convicted felon also got caught up in doling out impermissible benefits to players for nearly a decade to boost the university’s sports programs, mostly Hurricanes football. While there were never any legal charges, the school eventually suffered under a series of penalties for violating NCAA rules. The school lost scholarships, suffered setbacks in recruiting, and was hit with various suspensions. Shapiro was already let out of jail in 2020 thanks to COVID policies and was serving the rest of his sentence under house arrest. But now, according to TMZ , that is all behind him after Biden has canceled the rest of his sentence. Shapiro has still made no effort to repay any of the $82,657,362.29 he owes his victims. Follow Warner Todd Huston on Facebook at: facebook.com/Warner.Todd.Huston , or Truth Social @WarnerToddHustonHow major US stock indexes fared Monday, 12/9/2024
Syria rebel leader discusses 'transfer of power' after Assad's fallAs the U.S. government teeters on the brink of a fiscal crisis, Treasury Secretary Janet Yellen has issued a stark warning to Congress, calling for immediate action to raise or suspend the debt ceiling. The urgency of her message comes at a time when House Speaker Mike Johnson faces significant pressure to broker a deal, with the threat of losing his position hanging over his head. The current debt limit suspension expires on January 1, 2025. The federal debt currently stands at around $36 trillion. ET Year-end Special Reads Take That: The gamechanger weapon's India acquired in 2024 10 big-bang policy moves Modi government made in 2024 How governments tried to rein in the social media beast Yellen's Urgent Letter In a letter addressed to congressional leaders and highlighted in recent news, Yellen indicated that the U.S. could reach its debt limit as soon as mid-January 2025, necessitating the Treasury to deploy "extraordinary measures" to prevent default on national debt obligations. These measures include accounting maneuvers like suspending investments in certain federal employee retirement funds to manage cash flow without breaching the debt ceiling. However, Yellen stressed that these are stopgap solutions, not long-term answers, and a failure to act could lead to an "economic catastrophe". AP FILE - U.S. Treasury Secretary Janet Yellen speaks during a visit to the Financial Crimes Enforcement Network (FinCEN) in Vienna, Va., on Jan. 8, 2024. (AP Photo/Susan Walsh, File) The Political Scenario Speaker Mike Johnson finds himself in a precarious situation. With the Republican party holding a slim majority in the House, any move towards raising the debt ceiling is fraught with political peril. Historically, the debt ceiling has been a contentious issue, often used as leverage for broader fiscal policy discussions. Johnson's challenge is compounded by the internal dynamics of his party, where conservative hardliners are vehemently against raising the debt ceiling without significant spending cuts or policy concessions. The situation is further complicated by the timing. With a new debt limit set to be established on January 2, 2025, after the suspension ends, Johnson must navigate a political minefield where failure to act could lead to a default, potentially tanking the U.S. credit rating and sending shockwaves through global market. Artificial Intelligence(AI) Java Programming with ChatGPT: Learn using Generative AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Basics of Generative AI: Unveiling Tomorrows Innovations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Mastering C++ Fundamentals with Generative AI: A Hands-On By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Master in Python Language Quickly Using the ChatGPT Open AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Performance Marketing for eCommerce Brands By - Zafer Mukeri, Founder- Inara Marketers View Program Office Productivity Zero to Hero in Microsoft Excel: Complete Excel guide 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance A2Z Of Money By - elearnmarkets, Financial Education by StockEdge View Program Marketing Modern Marketing Masterclass by Seth Godin By - Seth Godin, Former dot com Business Executive and Best Selling Author View Program Astrology Vastu Shastra Course By - Sachenkumar Rai, Vastu Shashtri View Program Strategy Succession Planning Masterclass By - Nigel Penny, Global Strategy Advisor: NSP Strategy Facilitation Ltd. View Program Data Science SQL for Data Science along with Data Analytics and Data Visualization By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) AI and Analytics based Business Strategy By - Tanusree De, Managing Director- Accenture Technology Lead, Trustworthy AI Center of Excellence: ATCI View Program Web Development A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital Marketing Masterclass by Pam Moore By - Pam Moore, Digital Transformation and Social Media Expert View Program Artificial Intelligence(AI) AI-Powered Python Mastery with Tabnine: Boost Your Coding Skills By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital marketing - Wordpress Website Development By - Shraddha Somani, Digital Marketing Trainer, Consultant, Strategiest and Subject Matter expert View Program Office Productivity Mastering Google Sheets: Unleash the Power of Excel and Advance Analysis By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Mastering Full Stack Development: From Frontend to Backend Excellence By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Financial Literacy i.e Lets Crack the Billionaire Code By - CA Rahul Gupta, CA with 10+ years of experience and Accounting Educator View Program Data Science SQL Server Bootcamp 2024: Transform from Beginner to Pro By - Metla Sudha Sekhar, IT Specialist and Developer View Program Also Read: Donald Trump to be welcomed by new debt limit? Treasury Secretary Janet Yellen drops new bombshell Johnson under pressure For Johnson, this isn't just about policy; it's about political survival. The specter of losing his speakership looms large if he cannot unify his party or if he compromises too much with Democrats. On one hand, hardline fiscal conservatives within his party are traditionally opposed to raising the debt ceiling without substantial spending cuts. On the other hand, there is a growing call among more moderate Republicans and Democrats for a straightforward increase or elimination of the debt ceiling altogether. Also Read: U.S heading towards massive debt crisis, by early 2030s America will join a select club - Sudan, Eritrea and Venezuela Trump has publicly aligned with Democrats on this issue, suggesting that the debt ceiling should be eliminated entirely. His stance complicates Johnson's position as he navigates between appeasing party hardliners and addressing broader economic concerns that could arise from failing to raise the limit. Recent posts on X (formerly Twitter) have suggested that there's significant pressure on Johnson, with some within his party ready to leverage this situation to challenge his leadership. (You can now subscribe to our Economic Times WhatsApp channel )
Is Science Applications International Corporation (SAIC) An Undervalued Cybersecurity Stock to Buy?
BELLEVUE, Wash.--(BUSINESS WIRE)--Dec 5, 2024-- Smartsheet Inc. (NYSE: SMAR), the AI enhanced enterprise grade work management platform, today announced financial results for its third fiscal quarter ended October 31, 2024. The section titled "Use of Non-GAAP Financial Measures" below contains a description of the non-GAAP financial measures with a reconciliation between GAAP and non-GAAP information. The section titled "Definitions of Key Business Metrics" contains definitions of certain non-financial metrics provided within this press release. In a separate press release issued on September 24, 2024, we announced that we have entered into a definitive agreement ("Merger Agreement"), to be acquired by Blackstone and Vista Equity Partners. A copy of the press release and supplemental materials can be found on the "Investors" page of our website at and on the Securities and Exchange Commission, or the SEC, website at . Additional details and information about the terms and conditions of the Merger Agreement and the transactions contemplated by the Merger Agreement are available in the Current Report on Form 8-K filed with the SEC on September 24, 2024. Given the announced transaction, we will not be hosting an earnings conference call nor providing financial guidance in conjunction with this press release. For further detail and discussion of our financial performance, please refer to our third quarter 2025 Form 10-Q for the quarter ended October 31, 2024, filed today with the SEC. To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with GAAP, we use certain non-GAAP financial measures, as described below, to understand and evaluate our core operating performance. These non-GAAP financial measures, which may be different than similarly titled measures used by other companies, are presented to enhance investors’ overall understanding of our financial performance and should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measures to such GAAP measures can be found in the accompanying financial statements included with this press release. We believe that these non-GAAP financial measures provide useful information about our financial performance, enhance the overall understanding of our past performance and future prospects, and allow for greater transparency with respect to important metrics used by our management for financial and operational decision-making. We are presenting these non-GAAP financial metrics to assist investors in seeing our financial performance through the eyes of management, and because we believe that these measures provide an additional tool for investors to use in comparing our core financial performance over multiple periods with other companies in our industry. We define non-GAAP operating income as GAAP operating loss excluding share-based compensation expense, amortization of acquisition-related intangible assets, one-time costs associated with mergers and acquisitions, lease restructuring costs, and litigation expenses and settlements related to matters that are outside the ordinary course of our business, as applicable. We define non-GAAP net income as GAAP net income (loss) excluding non-recurring income tax adjustments associated with mergers and acquisitions and the same exclusions that are used to derive non-GAAP operating income. We define basic non-GAAP net income per share as non-GAAP net income divided by weighted-average shares outstanding ("WASO"). We define diluted non-GAAP net income per share as non-GAAP net income divided by diluted WASO. Diluted WASO includes the impact of potentially dilutive securities, which include stock options, restricted share units, performance share units, and shares subject to our 2018 employee stock purchase plan. There are a number of limitations related to the use of these non-GAAP measures as compared to GAAP operating loss and net income (loss), including that the non-GAAP measures exclude share-based compensation expense, which has been, and will continue to be for the foreseeable future, a significant recurring expense in our business and an important part of our compensation strategy. We use the non-GAAP financial measure of free cash flow, which is defined as GAAP net cash flows from operating activities, reduced by cash used for purchases of property and equipment (inclusive of spend on internal-use software) and principal payments on finance lease obligations. We believe free cash flow is an important liquidity measure of the cash that is available, after capital expenditures and operational expenses, for investment in our business, share repurchases, and potential acquisitions. Free cash flow is useful to investors as a liquidity measure because it measures our ability to generate excess cash beyond what is required for our operations. Once our business needs and obligations are met, cash can be used to maintain a strong balance sheet and invest in future growth. There are a number of limitations related to the use of free cash flow as compared to net cash from operating activities, including that free cash flow includes capital expenditures, the benefits of which are realized in periods subsequent to those when expenditures are made. We define annualized recurring revenue, or ARR, as the annualized recurring value of all active subscription contracts at the end of a reporting period. We exclude the value of non-recurring revenue streams, such as our professional services revenue, that are recognized at a point in time. We use ARR as one of our operating measures to assess the strength of the Company’s subscription services. ARR is a performance metric and should be viewed independently of revenue and deferred revenue, and is not intended to be a substitute for, or combined with, any of these items. Both multi-year contracts and contracts with terms less than one year are annualized by dividing the total committed contract value by the number of months in the subscription term and then multiplying by 12. Annualizing contracts with terms less than one year results in amounts being included in our ARR calculation that are in excess of the total contract value for those contracts at the end of the reporting period. The value of subscription contracts that are sold through third-party resellers, wherein we do not have visibility into the pricing provided, is based on the list price. We use average ARR per domain-based customer to measure customer commitment to our platform and sales force productivity. We define average ARR per domain-based customer as total outstanding ARR for domain-based subscriptions as of the end of the reporting period divided by the number of domain-based customers as of the same date. We define domain-based customers as organizations with a unique email domain name. We calculate dollar-based net retention rate as of a period end by starting with the ARR from the cohort of all customers as of the 12 months prior to such period end (“Prior Period ARR”). We then calculate the ARR from these same customers as of the current period end (“Current Period ARR”). Current Period ARR includes any upsells and is net of contraction or attrition over the trailing 12 months, but excludes subscription revenue from new customers in the current period. We then divide the total Current Period ARR by the total Prior Period ARR to arrive at the dollar-based net retention rate. Any ARR obtained through merger and acquisition transactions does not affect the dollar-based net retention rate until one year from the date on which the transaction closed. The dollar-based net retention rate is used by us to evaluate the long-term value of our customer relationships and is driven by our ability to retain and expand the subscription revenue generated from our existing customers. Smartsheet (NYSE: SMAR) is the modern enterprise work management platform trusted by millions of people at companies across the globe, including over 85% of the 2024 Fortune 500 companies. The category pioneer and market leader, Smartsheet delivers powerful solutions fueling performance and driving the next wave of innovation. Visit to learn more. Smartsheet announces material information to its investors using SEC filings, press releases, public conference calls, and on its investor relations page of the company’s website at . Subscription $ 273,703 $ 232,470 $ 786,328 $ 659,993 Professional services 13,168 13,448 39,939 41,396 Total revenue 286,871 245,918 826,267 701,389 Subscription 41,445 34,258 115,216 101,009 Professional services 12,291 12,780 36,693 38,948 Total cost of revenue 53,736 47,038 151,909 139,957 Gross profit 233,135 198,880 674,358 561,432 Research and development 63,477 58,257 189,514 172,805 Sales and marketing 127,854 137,920 383,315 382,685 General and administrative 45,155 38,153 124,489 109,654 Total operating expenses 236,486 234,330 697,318 665,144 Loss from operations (3,351 ) (35,450 ) (22,960 ) (103,712 ) Interest income 8,272 6,976 24,934 18,040 Other income (expense), net 47 (790 ) (593 ) (1,381 ) Income (loss) before income tax provision 4,968 (29,264 ) 1,381 (87,053 ) Income tax provision 3,644 3,164 1,057 8,602 Net income (loss) $ 1,324 $ (32,428 ) $ 324 $ (95,655 ) Net income (loss) per share, basic $ 0.01 $ (0.24 ) $ 0.00 $ (0.71 ) Net income (loss) per share, diluted $ 0.01 $ (0.24 ) $ 0.00 $ (0.71 ) Weighted-average shares outstanding used to compute net income (loss) per share, basic 139,007 135,189 138,287 133,868 Weighted-average shares outstanding used to compute net income (loss) per share, diluted 142,668 135,189 141,306 133,868 Share-based compensation expense included in the condensed consolidated statements of operations was as follows (in thousands, unaudited): Cost of subscription revenue $ 2,983 $ 3,164 $ 9,055 $ 9,980 Cost of professional services revenue 1,485 1,777 4,734 5,602 Research and development 17,763 17,220 54,036 52,263 Sales and marketing 14,453 17,462 45,472 55,505 General and administrative 9,151 10,024 29,827 30,099 Total share-based compensation expense $ 45,835 $ 49,647 $ 143,124 $ 153,449 Current assets: Cash and cash equivalents $ 454,281 $ 282,094 Short-term investments 306,640 346,701 Accounts receivable, net of allowances of $5,335 and $6,560, respectively 200,436 238,708 Prepaid expenses and other current assets 69,840 64,366 Total current assets 1,031,197 931,869 Restricted cash 18 19 Deferred commissions 156,724 148,867 Property and equipment, net 39,139 42,362 Operating lease right-of-use assets 29,693 39,480 Intangible assets, net 20,635 27,960 Goodwill 141,477 141,477 Other long-term assets 4,408 5,445 Total assets $ 1,423,291 $ 1,337,479 Current liabilities: Accounts payable $ 1,128 $ 2,937 Accrued compensation and related benefits 74,840 77,453 Other accrued liabilities 37,309 30,534 Operating lease liabilities, current 15,288 16,040 Finance lease liabilities, current 255 216 Deferred revenue 556,320 568,670 Total current liabilities 685,140 695,850 Operating lease liabilities, non-current 23,936 33,100 Finance lease liabilities, non-current 279 455 Deferred revenue, non-current 4,095 1,785 Other long-term liabilities 696 434 Total liabilities 714,146 731,624 Shareholders’ equity: Preferred stock, no par value; 10,000,000 shares authorized, no shares issued or outstanding as of October 31, 2024 and January 31, 2024 — — Class A common stock, no par value; 500,000,000 shares authorized, 139,302,943 shares issued and outstanding as of October 31, 2024; 500,000,000 shares authorized, 136,884,011 shares issued and outstanding as of January 31, 2024 — — Class B common stock, no par value; 500,000,000 shares authorized, no shares issued and outstanding as of October 31, 2024 and January 31, 2024 — — Additional paid-in capital 1,621,429 1,468,805 Accumulated other comprehensive income (loss) 196 (146 ) Accumulated deficit (912,480 ) (862,804 ) Total shareholders’ equity 709,145 605,855 Total liabilities and shareholders’ equity $ 1,423,291 $ 1,337,479 Net income (loss) $ 324 $ (95,655 ) Adjustments to reconcile net income (loss) to net cash provided by operating activities: Share-based compensation expense 143,124 153,449 Depreciation and amortization 21,121 20,008 Net amortization of premiums (discounts) on investments (6,059 ) (8,746 ) Amortization of deferred commission costs 50,328 38,439 Unrealized foreign currency (gain) loss (577 ) 684 Non-cash operating lease costs 7,513 9,450 Impairment of long-lived assets 3,237 1,448 Other, net 5,495 3,089 Changes in operating assets and liabilities: Accounts receivable 33,770 16,541 Prepaid expenses and other current assets (5,576 ) 1,060 Other long-term assets (1,039 ) (1,401 ) Accounts payable (1,665 ) (997 ) Other accrued liabilities 6,656 4,100 Accrued compensation and related benefits (5,483 ) 2,021 Deferred commissions (58,185 ) (58,705 ) Deferred revenue (9,952 ) 25,439 Other long-term liabilities 262 278 Operating lease liabilities (10,544 ) (12,326 ) Net cash provided by operating activities 172,750 98,176 Purchases of short-term investments (235,421 ) (375,387 ) Maturities of short-term investments 281,965 281,900 Purchases of property and equipment (1,437 ) (2,097 ) Proceeds from sale of property and equipment 53 28 Capitalized internal-use software development costs (6,549 ) (7,850 ) Net cash provided by (used in) investing activities 38,611 (103,406 ) Proceeds from exercise of stock options 10,957 1,330 Taxes paid related to net share settlement of restricted stock units (14,896 ) (1,644 ) Proceeds from contributions to Employee Stock Purchase Plan 14,403 15,664 Principal payments of finance leases (141 ) — Repurchases of Class A Common Stock and related costs (50,000 ) — Net cash provided by (used in) financing activities (39,677 ) 15,350 Effects of changes in foreign currency exchange rates on cash, cash equivalents, and restricted cash 379 (248 ) Net increase in cash, cash equivalents, and restricted cash 172,063 9,872 Cash, cash equivalents, and restricted cash at beginning of period 282,442 223,757 Cash, cash equivalents, and restricted cash at end of period $ 454,505 $ 233,629 Cash paid for interest $ 43 $ — Cash paid for income tax 7,655 9,471 Accrued purchases of property and equipment, including internal-use software 1,081 1,264 Share-based compensation expense capitalized in internal-use software development costs 2,355 3,283 Right-of-use assets obtained in exchange for new operating lease liabilities 558 1,684 Right-of-use asset reductions related to operating leases 2,832 4,451 Purchases of fixed assets under finance leases — 693 Loss from operations $ (3,351 ) $ (35,450 ) $ (22,960 ) $ (103,712 ) Add: Share-based compensation expense (1) 46,842 50,170 145,511 154,919 Amortization of acquisition-related intangible assets (2) 2,308 2,701 7,320 8,117 Lease restructuring costs (3) 40 1,934 3,359 2,051 One-time acquisition costs 10,525 — 10,525 — Non-GAAP operating income $ 56,364 $ 19,355 $ 143,755 $ 61,375 Operating margin (1 )% (14 )% (3 )% (15 )% Non-GAAP operating margin 20 % 8 % 17 % 9 % Net income (loss) $ 1,324 $ (32,428 ) $ 324 $ (95,655 ) Add: Share-based compensation expense (1) 46,842 50,170 145,511 154,919 Amortization of acquisition-related intangible assets (2) 2,308 2,701 7,320 8,117 Lease restructuring costs (3) 40 2,142 3,359 2,258 One-time acquisition costs 10,525 — 10,525 — Non-GAAP net income $ 61,039 $ 22,585 $ 167,039 $ 69,639 Non-GAAP net income per share, basic $ 0.44 $ 0.17 $ 1.21 $ 0.52 Non-GAAP net income per share, diluted $ 0.43 $ 0.16 $ 1.18 $ 0.51 Weighted-average shares outstanding; basic 139,007 135,189 138,287 133,868 Effect of dilutive securities: Shares subject to outstanding common stock awards 3,661 3,232 3,019 3,653 Weighted-average common shares outstanding; diluted 142,668 138,421 141,306 137,521 Net cash provided by operating activities $ 63,528 $ 15,146 $ 172,750 $ 98,176 Less: Purchases of property and equipment (414 ) (702 ) (1,437 ) (2,097 ) Capitalized internal-use software development costs (1,232 ) (3,035 ) (6,549 ) (7,850 ) Principal payments of finance leases (89 ) — (141 ) — Free cash flow $ 61,793 $ 11,409 $ 164,623 $ 88,229 View source version on : CONTACT: Smartsheet Inc. Investor Relations Contact Aaron Turner Contact Lisa Henthorn KEYWORD: WASHINGTON UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: SOFTWARE DATA ANALYTICS FINANCE ARTIFICIAL INTELLIGENCE DATA MANAGEMENT PROFESSIONAL SERVICES TECHNOLOGY FINTECH SOURCE: Smartsheet Copyright Business Wire 2024. PUB: 12/05/2024 04:07 PM/DISC: 12/05/2024 04:06 PM
Swathes of social care market could collapse under £2.8bn cost pressures50 Cent Suggests Jay-Z Could Be Dropped By NFL As Producer Of Super Bowl Halftime Show After Rape Allegations
Carson Beck Landing Spots: Where Can the Georgia QB Go in the 2025 NFL Draft?REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the closing of its underwritten public offering of 16,576,088 shares of its common stock at a public offering price of $46.00 per share, before underwriting discounts and commissions, and, in lieu of shares of common stock, to certain investors, pre-funded warrants to purchase 2,173,917 shares of common stock at a public offering price of $45.9999, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. The shares of common stock issued and sold in the offering include 2,445,652 shares issued upon exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Revolution Medicines, were $862.5 million. All shares and pre-funded warrants in the offering were offered by Revolution Medicines. J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC and Guggenheim Securities acted as joint book-running managers for the offering. UBS Investment Bank acted as lead manager. A shelf registration statement relating to these securities was filed with the U.S. Securities and Exchange Commission (SEC) on March 4, 2024, and automatically became effective upon filing. This offering was made solely by means of a prospectus. A copy of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, a copy of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained by contacting: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846 or by email at TD.ECM_Prospectus@tdsecurities.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Revolution Medicines, Inc. Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 and RMC-5552. Revolution Medicines Investors & Media Contacts: investors@revmed.com; media@revmed.com
Unique among ‘Person of the Year’ designees, Donald Trump gets a fact-check from Time magazine
AI Stocks Soar! ServiceNow Impresses Analysts.// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC , Dec. 13, 2024 /CNW/ -- BioVaxys Technology Corp. BIOV 5LB (" BioVaxys " or the " Company ") is pleased to announce that it has closed the first tranche (the " First Tranche ") of its previously announced non-brokered private placement (the " Private Placement ") with the issuance of 2,200,000 units (the " Units ") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $110,000 . Each Unit consist of one (1) common share in the capital of the Company (each, a " Share ") and one (1) whole Share purchase warrant (each, a " Warrant "), whereby each Warrant is convertible into one additional Share at an exercise price of $0.15 until December 13, 2026 , being the date that is 24 months from the date of issue. The Company intends to use the net proceeds of the First Tranche for working capital. No finder's fees were paid in connection with the First Tranche. All securities issued pursuant to the First Tranche are subject to a statutory hold period expiring April 14, 2025 , being the date that is four months and one day from the date of issuance in accordance with applicable securities legislation In addition, the Company announces that it has entered into a debt settlement agreement with an arm's-length consultant of the Company to settle an aggregate of $500,000 in debt owed to the consultant by issuing 5,000,000 Shares at a deemed price of $0.10 per Share (the " Debt Settlement "). The board of directors of the Company has determined that it is in the best interests of the Company to settle the outstanding debt through the issuance of Shares in order to preserve the Company's cash for working capital purposes. All securities proposed to be issued pursuant to the Debt Settlement will be subject to a statutory hold period of four months from the date of issuance in accordance with applicable securities legislation. Closing of the Debt Settlement is conditional upon a number of conditions, including receipt of all applicable corporate and regulatory approvals, including the acceptance of the Canadian Securities Exchange. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States . The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933 , as amended (the " U.S. Securities Act "), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( www.biovaxys.com ), a company registered in British Columbia, Canada , is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPXTM immune-educating technology platform and it's HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. DPXTM is a patented antigen delivery platform that can incorporate a range of bioactive molecules to produce targeted, long-lasting immune responses enabled by various formulated components. The DPX platform facilitates antigen delivery to regional lymph nodes and has been demonstrated to induce robust and durable T cell and B cell responses in pre-clinical and clinical studies for both cancer and infectious disease. BioVaxys' common shares are listed on the Canadian Securities Exchange under the stock symbol "BIOV", on the Frankfurt Bourse 5LB , and quoted in the US on the OTC Markets. For more information, visit www.biovaxys.com and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed " James Passin " James Passin , Chief Executive Officer Phone: +1 740 358 0555 Cautionary Statements Regarding Forward Looking Information This news release includes certain "forward-looking information" and "forward-looking statements" (collectively " forward-looking statements ") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, the statements relating to the Private Placement and the Debt Settlement, including the expected use of proceeds from the Private Placement and related issuance of the Shares for the Debt Settlement, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the impact of any changes that may affect the anticipated use of proceeds from the Private Placement and the ability of the Company to obtain the necessary approvals to proceed with the Debt Settlement. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws. The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this press release and does not accept responsibility for the adequacy or accuracy of this release. Logo - https://mma.prnewswire.com/media/2415135/5078410/BioVaxys_Technology_Corp_Logo.jpg View original content: https://www.prnewswire.com/news-releases/biovaxys-announces-closing-of-first-tranche-of-private-placement-and-announces-debt-settlement-agreement-302331766.html SOURCE BioVaxys Technology Corp. View original content: http://www.newswire.ca/en/releases/archive/December2024/13/c5212.html © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.